Own stem cells may shield bone marrow during ovarian cancer chemo

NCT ID NCT05401162

Recruiting now Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce severe low white blood cell counts and other blood-related side effects, making treatment safer and more manageable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous haematopoietic stem cells
What this could lead to: If it works, this approach could make chemotherapy safer and more tolerable for ovarian cancer patients by speeding up blood cell recovery.
What could go wrong: This is a small, early-stage study with 40 participants, so results may not apply to all patients. Risks include infection, bleeding, or stem cell transfusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.